Evofem Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Operations
(In thousands, except share and per share data)
| 2023 | 2022 | |
|---|---|---|
| Net income (loss) | $52,979 | $(76,698) |
| Other comprehensive income: | ||
| Change in fair value of financial instruments attributed to credit risk change | 22,814 | 44,438 |
| Reclassification adjustment related to debt extinguishment | (73,187) | - |
| Comprehensive income (loss) | $2,606 | $(32,260) |
See accompanying notes to consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.